clofibrate has been researched along with Fatty Liver in 19 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preventive effects of dehydroepiandrosteone acetate (DHEA-A) and clofibrate (positive control substance) on the fatty liver induced by orotic acid (OA) were examined on the male Sprague-Dawley rats fed a high sucrose based diet containing 1% OA and this diet further mixed with 0." | 7.70 | Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats. ( Goto, H; Makita, T; Yamashita, S, 1998) |
| "The addition of 1 per cent orotic acid to a sucrose-enriched semipurified diet results in markedly fatty liver when fed to rats for 7 to 22 days." | 7.65 | Reversal of orotic acid-induced fatty liver in rats by clofibrate. ( Edelstein, D; Novikoff, PM, 1977) |
| "Non-alcohol-induced steatohepatitis (NASH) is characterized by elevated serum aminotransferase activities with hepatic steatosis, inflammation, and occasionally fibrosis that may progress to cirrhosis." | 5.29 | Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. ( Crippin, JS; Gores, GJ; Gossard, A; Laurin, J; Lindor, KD; Ludwig, J; McGill, DB; Rakela, J, 1996) |
| "All animals were fed HFD but only 2/12 animals were fed HFD plus clofibrate-developed fatty liver." | 3.72 | Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. ( Akbiyik, F; Bozkaya, H; Cinar, K; Demirpence, E; Haziroglu, R; Ozsullu, T; Tunca, R; Uzunalimoglu, O; Yurdaydin, C, 2004) |
| "Preventive effects of dehydroepiandrosteone acetate (DHEA-A) and clofibrate (positive control substance) on the fatty liver induced by orotic acid (OA) were examined on the male Sprague-Dawley rats fed a high sucrose based diet containing 1% OA and this diet further mixed with 0." | 3.70 | Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats. ( Goto, H; Makita, T; Yamashita, S, 1998) |
| "The addition of 1 per cent orotic acid to a sucrose-enriched semipurified diet results in markedly fatty liver when fed to rats for 7 to 22 days." | 3.65 | Reversal of orotic acid-induced fatty liver in rats by clofibrate. ( Edelstein, D; Novikoff, PM, 1977) |
| "All clofibrate pretreated steatohepatitic mice receiving APAP exhibited lower liver injury, which did not progress and the mice survived." | 1.35 | Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. ( Bhave, VS; Donthamsetty, S; Latendresse, JR; Mehendale, HM; Mitra, MS, 2008) |
| "Pretreatment with clofibrate results in partial reversal of changes produced by valproate." | 1.33 | Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. ( Balasubramanian, KA; Eapen, CE; Natarajan, SK; Pullimood, AB, 2006) |
| "Treatment with clofibrate, a PPARalpha-activating ligand, led to a marked decrease in fatty liver and complete abrogation of necroinflammatory changes in FE rats." | 1.32 | Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. ( Bass, NM; Dannenberg, AJ; Jokelainen, K; Nanji, AA, 2004) |
| "Non-alcohol-induced steatohepatitis (NASH) is characterized by elevated serum aminotransferase activities with hepatic steatosis, inflammation, and occasionally fibrosis that may progress to cirrhosis." | 1.29 | Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. ( Crippin, JS; Gores, GJ; Gossard, A; Laurin, J; Lindor, KD; Ludwig, J; McGill, DB; Rakela, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (63.16) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nanji, AA | 1 |
| Dannenberg, AJ | 1 |
| Jokelainen, K | 1 |
| Bass, NM | 1 |
| Akbiyik, F | 1 |
| Cinar, K | 1 |
| Demirpence, E | 1 |
| Ozsullu, T | 1 |
| Tunca, R | 1 |
| Haziroglu, R | 1 |
| Yurdaydin, C | 1 |
| Uzunalimoglu, O | 1 |
| Bozkaya, H | 1 |
| Natarajan, SK | 1 |
| Eapen, CE | 1 |
| Pullimood, AB | 1 |
| Balasubramanian, KA | 1 |
| Tanaka, N | 1 |
| Moriya, K | 1 |
| Kiyosawa, K | 1 |
| Koike, K | 1 |
| Gonzalez, FJ | 1 |
| Aoyama, T | 1 |
| Donthamsetty, S | 1 |
| Bhave, VS | 1 |
| Mitra, MS | 1 |
| Latendresse, JR | 1 |
| Mehendale, HM | 1 |
| Laurin, J | 1 |
| Lindor, KD | 1 |
| Crippin, JS | 1 |
| Gossard, A | 1 |
| Gores, GJ | 1 |
| Ludwig, J | 1 |
| Rakela, J | 1 |
| McGill, DB | 1 |
| Goto, H | 1 |
| Yamashita, S | 1 |
| Makita, T | 1 |
| Cenedella, RJ | 1 |
| Takashima, K | 1 |
| Ohyama, K | 1 |
| Mori, T | 1 |
| Takeyama, S | 1 |
| Novikoff, PM | 2 |
| Edelstein, D | 2 |
| Müting, D | 1 |
| Hanefeld, M | 1 |
| Jaross, W | 1 |
| Trübsbach, A | 1 |
| Leonhardt, W | 1 |
| Roheim, PS | 1 |
| Novikoff, AB | 1 |
| Barter, PJ | 1 |
| Nestel, PJ | 1 |
| Carroll, KF | 1 |
| Mertz, DP | 1 |
| Schwoerer, P | 1 |
| Babucke, G | 1 |
| Westerfeld, WW | 2 |
| Elwood, JC | 2 |
| Richert, DA | 2 |
| Kähönen, MT | 1 |
| Yilkahri, RH | 1 |
| Hassinen, I | 1 |
| Metelitsa, VI | 1 |
| Matova, EE | 1 |
| Aptekar', SG | 1 |
19 other studies available for clofibrate and Fatty Liver
| Article | Year |
|---|---|
Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation.
Topics: Acyl-CoA Oxidase; Animals; Carrier Proteins; Clofibrate; Cyclooxygenase 2; Ethanol; Fatty Acid-Bindi | 2004 |
Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Oxidase; Animals; Antioxidants; Body Weight; Clofibrate; Dietary Fa | 2004 |
Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes.
Topics: Animals; Anticholesteremic Agents; Clofibrate; Disease Models, Animal; Enzyme Inhibitors; Fatty Live | 2006 |
PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Clofibrate; DNA Damage; Fatty Acids; Fatty L | 2008 |
Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate.
Topics: Acetaminophen; Adenosine Triphosphate; Alanine Transaminase; Animals; Clofibrate; Cytochrome P-450 C | 2008 |
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Clofibrate; Drug | 1996 |
Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats.
Topics: Animals; Clofibrate; Dehydroepiandrosterone; Diet; Fatty Liver; Hypolipidemic Agents; Liver; Male; M | 1998 |
Hepatic triglyceride lipases--effect of clofibrate and halofenate.
Topics: Animals; Clofibrate; Fatty Acids, Nonesterified; Fatty Liver; Glycolates; Halofenate; Hydrogen-Ion C | 1976 |
Hypolipidemic effect of alpha-mono-p-myristyloxy-alpha'-methylcinnamoyl glycerol (LK-903) in rats.
Topics: Animals; Cinnamates; Clofibrate; Diet; Fatty Liver; Glycerides; Hypolipidemic Agents; Intubation, Ga | 1978 |
Reversal of orotic acid-induced fatty liver in rats by clofibrate.
Topics: Animals; Apoproteins; Clofibrate; Endoplasmic Reticulum; Fatty Liver; Golgi Apparatus; Liver; Male; | 1977 |
[Therapy of fatty liver].
Topics: Clofibrate; Diet Therapy; Fatty Liver; Humans; Nicotinic Acids; Phospholipids | 1974 |
[Effect of chlorfibrinic acid on the triglyceride and glycogen contents of human liver as well as on blood-level forming metabolites].
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; | 1972 |
Production and prevention of fatty liver in rats fed clofibrate and orotic acid diets containing sucrose.
Topics: Animals; Apoproteins; Cholesterol; Clofibrate; Diet; Drug Synergism; Endoplasmic Reticulum; Fatty Li | 1974 |
Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration, and alcoholic fatty liver.
Topics: Adolescent; Adult; Alcoholism; Blood Glucose; Carbon Isotopes; Clofibrate; Dietary Carbohydrates; Fa | 1972 |
[Classification of hyperlipoproteinaemia in primary gout].
Topics: Adult; Aged; Arteriosclerosis; Blood Protein Disorders; Body Weight; Carbohydrate Metabolism; Clofib | 1972 |
Effect of clofibrate on the handling of dietary and liver fat.
Topics: Animals; Cholesterol; Clofibrate; Diet; Electrophoresis, Disc; Enzyme Activation; Fatty Liver; Gluco | 1972 |
A comparison of hypolipidemic drugs in the prevention of an orotic acid fatty liver.
Topics: Animals; Clofibrate; Diet; Electrophoresis; Ethylamines; Fatty Liver; Glucosephosphate Dehydrogenase | 1972 |
Studies on the mechanism of inhibition of acute alcoholic fatty liver by clofibrate.
Topics: Acetone; Animals; Clofibrate; Ethanol; Fatty Acids, Nonesterified; Fatty Liver; Glucose; Glycerophos | 1972 |
[Experimental lipoidosis of the aorta in rabbits with endogenous hypercholesteremia and without anisotropic adiposis of the liver].
Topics: Adipose Tissue; Aminocaproates; Animals; Aorta; Cholesterol; Clofibrate; Dietary Fats; Disease Model | 1971 |